Development
BioXcel Therapeutics, Inc.
BTAI
$1.84
$0.3120.26%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -54.37% | -66.23% | -67.00% | -55.01% | -34.53% |
| Total Depreciation and Amortization | -0.31% | 4.14% | 6.80% | 10.10% | 21.05% |
| Total Amortization of Deferred Charges | 157.99% | 282.55% | -- | -- | -- |
| Total Other Non-Cash Items | 33.27% | 35.46% | 10.14% | -7.95% | -34.80% |
| Change in Net Operating Assets | 457.48% | 10,400.53% | 1,128.21% | 126.49% | 184.59% |
| Cash from Operations | -43.00% | -51.81% | -63.58% | -64.74% | -41.39% |
| Capital Expenditure | 86.75% | 88.10% | 92.37% | 68.76% | 78.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 86.75% | 88.10% | 92.37% | 68.76% | 78.52% |
| Total Debt Issued | -100.00% | -56.27% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10,721.89% | 9,768.36% | -75.20% | -99.72% | -99.81% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 72.07% | 72.07% | -- | -- | 85.15% |
| Cash from Financing | -74.58% | -17.69% | 18.50% | -6.06% | -6.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -591.10% | -167.41% | -643.83% | -297.71% | -205.72% |